Codexis Announces New Employment Inducement Grants
Codexis (NASDAQ: CDXS) has announced the approval of an equity grant for one new employee. The inducement award includes 50,000 stock options and 15,000 restricted stock units (RSUs) under the company's 2024 Inducement Plan. The stock options will vest over four years, with 25% vesting after the first year and the remainder vesting monthly. The RSUs will vest in equal annual installments over three years. Both grants are subject to continued employment with Codexis.
Codexis (NASDAQ: CDXS) ha annunciato l'approvazione di un'indennità azionaria per un nuovo dipendente. Il premio di indennità include 50.000 opzioni su azioni e 15.000 unità di azioni vincolate (RSU) secondo il Piano di Indennità 2024 dell'azienda. Le opzioni su azioni matureranno in un periodo di quattro anni, con il 25% che matura dopo il primo anno e il restante che matura mensilmente. Le RSU matureranno in rate annuali uguali per tre anni. Entrati premi sono soggetti a continuare l'impiego con Codexis.
Codexis (NASDAQ: CDXS) ha anunciado la aprobación de una concesión de acciones para un nuevo empleado. La concesión de incentivo incluye 50,000 opciones sobre acciones y 15,000 unidades de acciones restringidas (RSUs) bajo el Plan de Incentivos 2024 de la empresa. Las opciones sobre acciones se consolidarán durante cuatro años, con un 25% consolidándose después del primer año y el resto consolidándose mensualmente. Las RSUs se consolidarán en pagos anuales iguales durante tres años. Ambas concesiones están sujetas a la continuación del empleo en Codexis.
코덱시스 (NASDAQ: CDXS)가 새로운 직원에 대한 주식 보상을 승인했다고 발표했습니다. 유인 보상에는 회사의 2024 유인 계획에 따라 50,000 주식 옵션과 15,000 제한 주식 단위 (RSU)가 포함됩니다. 주식 옵션은 4년 동안 분만되며, 첫해에 25%가 분할되고 나머지는 매월 분할됩니다. RSU는 3년에 걸쳐 매년 동일한 비율로 배분됩니다. 두 가지 보상은 코덱시스에서 계속 근무해야 합니다.
Codexis (NASDAQ: CDXS) a annoncé l'approbation d'une attribution d'actions pour un nouvel employé. La récompense d'incitation comprend 50 000 options d'achat d'actions et 15 000 unités d'actions restreintes (RSU) au titre du plan d'incitation 2024 de l'entreprise. Les options d'achat d'actions seront acquises sur une période de quatre ans, avec 25 % acquises après la première année et le reste acquises mensuellement. Les RSU seront acquises en paiements annuels égaux sur trois ans. Les deux attributions sont soumises à la poursuite de l'emploi avec Codexis.
Codexis (NASDAQ: CDXS) hat die Genehmigung eines Aktienzuschusses für einen neuen Mitarbeiter bekannt gegeben. Die Incentive-Auszeichnung umfasst 50.000 Aktienoptionen und 15.000 eingeschränkte Aktieneinheiten (RSUs) im Rahmen des Unternehmensplans für 2024. Die Aktienoptionen verfallen über einen Zeitraum von vier Jahren, wobei 25 % nach dem ersten Jahr und der Rest monatlich verfallen. Die RSUs verfallen in gleichen jährlichen Raten über drei Jahre. Beide Zuschüsse stehen unter dem Vorbehalt einer fortgesetzten Beschäftigung bei Codexis.
- None.
- None.
REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of an equity grant to one new employee as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employee received an equity award consisting of (i) options to purchase 50,000 shares of Codexis common stock and (ii) 15,000 restricted stock units (RSUs) as an inducement award under the company’s 2024 Inducement Plan.
The stock options have an exercise price equal to the closing price per share of Codexis’ common stock as reported by Nasdaq on the grant date, and vest over four years, with 25 percent of the shares vesting on the first anniversary of the vesting commencement date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to the employee’s continued service with Codexis through the applicable vesting dates. The RSUs will vest in equal annual installments on each anniversary of the grant date, until the third anniversary of such date, subject to the employee’s continued service with Codexis through the applicable vesting dates.
Codexis is providing this information in accordance with Nasdaq Listing Rule 5635(c)4.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule and nucleic acid therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
FAQ
What equity grants did Codexis (CDXS) announce for new employees in November 2023?
What is the vesting schedule for Codexis (CDXS) new employee stock options?
How do the RSUs vest in Codexis (CDXS) new employee equity grant?
